LIVZON PHARMA (01513) announced its first half 2025 results, with operating revenue of approximately 6.272 billion yuan, down 0.17% year-over-year; net profit attributable to listed company shareholders of approximately 1.281 billion yuan, up 9.4% year-over-year; and basic earnings per share of 1.43 yuan.

In the first half, the company's various business segments worked synergistically, driving overall operations to demonstrate steady progress with positive momentum. From a revenue perspective, major products in the digestive, psychiatric and neurological, reproductive, and traditional Chinese medicine segments all achieved year-over-year growth; the API and intermediates segment saw overall revenue decline slightly due to price fluctuations in the domestic market for cephalosporin APIs; the diagnostic reagents and equipment segment experienced a small revenue decline due to respiratory product cycle changes, coming off a high base from the first half of 2024.

From a profit perspective, growth in the formulations segment and increased exports of high-margin specialty APIs in the API segment drove profit increases; meanwhile, through continuous improvement in operational efficiency and cost reduction initiatives, both total profit and non-GAAP net profit attributable to shareholders achieved substantial growth.

As of July 31, 2025, the company had 39 formulation products in its R&D pipeline. By development stage, 13 projects are in the marketing application phase, 4 in Phase III clinical trials, 2 in process validation/BE phase, and 4 in Phase II clinical trials. Leveraging optimized R&D management and deep application of AI digital tools, the first half saw intensive materialization of R&D achievements.